Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic
semaglutide
anti-diabetic and weight-loss drugs to hit the market early next year, a top official said.
The company is looking at a 'good' share of the market,
Krishnakumar Vaidyanathan
, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction.
Productivity Tool
Zero to Hero in Microsoft Excel: Complete Excel guide
By Metla Sudha Sekhar
View Program
Finance
Introduction to Technical Analysis & Candlestick Theory
By Dinesh Nagpal
View Program
Finance
Financial Literacy i e Lets Crack the Billionaire Code
By CA Rahul Gupta
View Program
Digital Marketing
Digital Marketing Masterclass by Neil Patel
By Neil Patel
View Program
Finance
Technical Analysis Demystified- A Complete Guide to Trading
By Kunal Patel
View Program
Productivity Tool
Excel Essentials to Expert: Your Complete Guide
By Study at home
View Program
Artificial Intelligence
AI For Business Professionals Batch 2
By Ansh Mehra
View Program
Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026.
'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.'
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Live Events
Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide.
Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'
Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world.
'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said.
'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.'
Dr Reddy's Labs,
Sun Pharmaceutical Industries
,
Cipla
,
Mankind Pharma
,
Torrent Pharmaceuticals
, and
Zydus Lifesciences
are also among Indian drugmakers readying to launch generic semaglutide next year.
Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September.
'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.'
Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
XRP price prediction: XRP rebounds from $2.80 — is the road to $5 finally wide open?
XRP is once again back in the spotlight. After bouncing off a critical support zone at $2.80, XRP surged nearly 24% in recent sessions, reaching $2.95 today. With growing investor optimism, favorable regulatory momentum, and increasing chatter around XRP ETFs, many are now asking — can XRP hit the long-anticipated $5 mark in August 2025? XRP price retests $2.80 support and rebounds strongly The recent bounce from the $2.80 level came at a crucial moment for XRP. After weeks of consolidation and growing pressure from broader crypto market volatility, XRP managed to hold ground — signaling a potential trend reversal. The token is currently trading around $2.95 , down about 3.9% in the past 24 hours but still well above recent lows. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program This support level is critical because it's been tested multiple times in the past three months. Holding above $2.80 suggests strong buying interest, especially as bulls eye higher resistance targets in the near term. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This New AC Cooler Cools the Room In Seconds Coldeez Cooling Ace XRP price forecast: Bulls now target the $3.67 resistance zone After reclaiming momentum from the $2.80 level, the next logical target for XRP is the $3.67 resistance , a level it briefly touched during its July rally. Technical analysts believe a close above this level could trigger a broader breakout toward $4.00 and beyond. If XRP manages to break and sustain above $3.67, analysts expect a fresh bullish wave that could quickly bring it closer to the psychological $5 barrier . A continued uptick in volume and favorable news around Ripple's ongoing legal clarity could act as key drivers in this push. Live Events Is a breakout imminent? XRP shows bullish pattern forming Chart watchers are closely monitoring XRP's current setup, which is forming a falling wedge pattern — typically a bullish indicator in crypto technical analysis. The resistance trendline currently sits around $3.03 , and a breakout above this could act as the first confirmation of renewed upward momentum. Many traders believe XRP is entering a 'make-or-break' zone this August. If support at $2.90–$3.00 holds and volume increases, the breakout could come faster than expected. XRP ETF approval rumors spark investor interest One of the biggest catalysts currently driving optimism around XRP is growing speculation about an XRP ETF approval in the United States. Reports suggest that with a more crypto-friendly SEC leadership under the Trump administration, the odds of an XRP-based ETF have risen dramatically — some estimating a 95% likelihood of approval by the end of the year. Such an approval would open the floodgates for institutional capital and could mirror the price surges seen in Bitcoin and Ethereum after their respective ETF greenlights. Regulatory clarity and Ripple's momentum could fuel rally Beyond ETF news, XRP is also benefitting from recent court rulings affirming that XRP is not a security — removing one of the largest regulatory clouds hanging over the asset. Ripple, the company behind XRP, continues to expand its global partnerships and push for blockchain adoption in cross-border payments. As regulatory clarity improves and institutional demand builds, XRP is emerging as a top altcoin pick for many long-term investors. Where is XRP headed next? Key predictions for August 2025 Several price prediction platforms and analysts have updated their forecasts for XRP in August 2025: Short-Term Forecast : Many models suggest XRP could climb to $3.12–$4.45 by the end of August, especially if support continues holding and volume rises. Mid-Term Outlook : With ETF optimism and regulatory momentum, XRP could realistically reach $5–$5.50 by late 2025. Bull Case Scenario : Some bullish forecasts project XRP moving toward $6–$8 , or even $10+ , if broader crypto markets rally and tokenized finance takes off globally. Bearish Risk : A break below the $2.80–$2.60 zone could invalidate the bullish setup and send XRP back into consolidation or worse, correction territory. What should investors watch now? As XRP navigates a pivotal month, here are the most important things to keep an eye on: $3.03 resistance — A breakout above this could mark the start of the next leg higher. $2.80 support — Holding this is crucial for maintaining the current bullish setup. Regulatory headlines — Any news on ETF filings or SEC decisions could spark strong price reactions. Market sentiment — Bitcoin and Ethereum trends often influence XRP, so broader market conditions remain highly relevant. Is XRP ready to break past $5? August 2025 is shaping up to be a turning point for XRP. The recent price rebound from $2.80 has re-energized bulls, and with regulatory clarity improving and the possibility of an ETF on the horizon, XRP has a strong case for a breakout. While nothing is guaranteed in crypto markets, the road to $5 now looks more realistic than ever. Traders and investors would be wise to watch XRP closely this month — it just might be gearing up for its biggest move yet. FAQs: 1. What is the latest XRP price prediction for August 2025? XRP could climb toward $5 if it holds support and breaks key resistance levels in August. 2. Can XRP really reach $5 after rebounding from $2.80? Yes, strong support at $2.80 and ETF news may drive XRP closer to the $5 mark.
The Hindu
2 hours ago
- The Hindu
DAC approves defence procurement worth ₹67,000 crore to strengthen border security
The Defence Acquisition Council (DAC), chaired by Defence Minister Rajnath Singh, sanctioned multiple procurement proposals worth nearly ₹67,000 crore to strengthen the nation's military preparedness. According to the Ministry of Defence (MoD), for the Indian Army, Acceptance of Necessity (AoN) was accorded for the procurement of Thermal Imager-based Driver Night Sight for BMP. This would enhance night driving capability of BMP and provide higher mobility and operational advantage to the mechanised infantry. For the Indian Navy, AoN was accorded for the procurement of Compact Autonomous Surface Craft, BrahMos Fire Control System and launchers, and upgradation of BARAK-1 point defence missile system. The procurement of Compact Autonomous Surface Craft will provide the capability to the Navy for detection, classification and neutralisation of threats in anti-submarine warfare missions. For the Indian Air Force, AoN for procurement of mountain radars and upgradation of Saksham/Spyder weapon system was accorded. Mountain radars will enhance the air surveillance capability along and across the borders in the mountainous regions. The upgradation of Saksham/Spyder system for integration with Integrated Air Command and Control System will enhance the air defence capability, said the MoD in a statement. AoN was also accorded for the procurement of Medium Altitude Long Endurance (MALE) Remotely Piloted Aircraft (RPAs) for the three services. The proposed MALE RPAs can carry multiple payloads and weapons and operate at longer ranges for long endurance missions. They will significantly enhance round-the-clock surveillance and combat capability of the armed forces. In addition, the DAC has also accorded AoN for sustenance of C-17 and C-130J fleets and comprehensive annual maintenance contract of S-400 Long Range Air Defence Missile System.
Time of India
2 hours ago
- Time of India
AMD's restricted access to China's AI chip market may heavily dent revenue despite a strong Q3 forecast; here's why
Advanced Micro Devices ( AMD ) forecast third-quarter revenue above Wall Street estimates on Tuesday (August 5, 2025) but warned that its access to the China market remains uncertain due to the pending review of its license applications to export its MI308 chips to the East Asian country. AMD, the second-largest maker of AI accelerator chips, is betting on upbeat demand for its artificial intelligence chips from businesses rushing to expand infrastructure to dominate the latest technology. Shares of the Santa Clara, California-based company rose 2% in extended trading. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program AMD's Q3 projections by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Tiger meeting her former zookeeper after 5 years. See what happens next! Story To Hear The company expects revenue of about $8.7 billion for the third quarter, plus or minus $300 million, compared with analysts' average estimate of $8.30 billion, according to data compiled by LSEG. The outlook does not include any revenue from AMD's AI chip MI308's shipments to China, as license applications are currently under review by the US government, the company said. Live Events The company said last month the Department of Commerce would review its license applications to export its MI308 chips to China, and it plans to resume those shipments when licenses are approved, after U.S. curbs announced in April required it to obtain a license to ship advanced AI processors to China. AMD had forecast a $1.5 billion hit to revenue this year due to these curbs, with most of the impact affecting the second and third quarters. AMD shares 2025 performance AMD's shares have climbed more than 40% this year, far outpacing a nearly 12% jump in the benchmark chip index, as investors bet on the company's ability to capitalize on the widespread use of AI. Demand for AMD processors remains strong Demand remains robust for AMD's advanced processors that power complex AI systems for Microsoft, Meta Platforms, generative AI leader OpenAI, and other customers, with the company set to benefit from cloud giants bumping up their hefty spending plans for building AI infrastructure. Meta has raised the bottom end of its annual capital expenditure forecast by $2 billion, to a range of between $66 billion and $72 billion. Similarly, Microsoft forecast a record $30 billion in capital spending for the first quarter of the current fiscal year to meet soaring AI demand.
